CJC-1295 DAC 5mg

CJC-1295 with DAC – 2 mg | For Research Use Only – Not for Human Consumption

CJC-1295 with DAC (Drug Affinity Complex) is a synthetic tetrasubstituted analog of growth hormone–releasing hormone (GHRH 1–29), developed to enhance and sustain endogenous growth hormone (GH) secretion in preclinical models. The covalent attachment of a Drug Affinity Complex (DAC) to the peptide confers prolonged systemic half-life via albumin binding, enabling stable elevation of both GH and insulin-like growth factor-1 (IGF-1) levels over an extended period.

Mechanistic Overview

CJC-1295 acts as a GHRH receptor agonist, stimulating pituitary somatotrophs to release GH in a physiologically pulsatile manner. The incorporation of DAC enables reversible binding to serum albumin, thereby protecting the peptide from proteolytic degradation and extending its plasma residence time up to 8–10 days in research models.

Due to the presence of the Drug Affinity Complex and the peptide’s higher molecular weight and hydrophobic character, CJC-1295 with DAC demonstrates increased resistance to solubilization compared to non-DAC peptides. In laboratory settings, this material may require a greater volume of bacteriostatic water and/or the use of acidified bacteriostatic water to achieve full dissolution during reconstitution for analytical or experimental preparation. This characteristic is inherent to DAC-modified peptides and does not indicate degradation or impurity.

Key investigational effects include:

• Stimulation of GH and IGF-1 release, mimicking endogenous hormone dynamics
• Promotion of anabolic activity, including muscle hypertrophy and protein synthesis
• Support for lipolysis and fat metabolism regulation
• Improved recovery and repair of musculoskeletal tissue in preclinical models
• Modulation of metabolic pathways linked to cellular regeneration and longevity

Research Applications

CJC-1295 with DAC is employed in in vitro and in vivo studies exploring:

• Growth hormone deficiency modeling and replacement strategies
• Anabolic and anti-catabolic mechanisms in muscle tissue
• GH/IGF-1 axis regulation in metabolic and endocrine disorders
• Age-related decline in somatotropic activity
• Extended-release peptide delivery systems and pharmacokinetics

The extended half-life and sustained GH stimulation profile make CJC-1295 with DAC particularly valuable for studying long-acting peptide therapeutics and albumin-binding delivery technologies.

Product Specifications

• Peptide Content: 2 mg (lyophilized)
• Modification: Tetrasubstituted GHRH analog with Drug Affinity Complex (DAC)
• Purity: >98% (validated via HPLC & MS)
• Storage: Store lyophilized at –20°C. Refrigerate reconstituted material at 2–8°C and use within the designated research timeline

Regulatory & Legal Notice

THIS PRODUCT IS INTENDED FOR RESEARCH USE ONLY. NOT FOR HUMAN OR ANIMAL CONSUMPTION.

This designation allows the use of research chemicals strictly for in-vitro testing and laboratory experimentation only. All product information provided is for educational purposes only. Bodily introduction of any kind into humans or animals is strictly forbidden by law.

This product should only be handled by licensed, qualified professionals. This product is not a drug, food, or cosmetic and may not be misbranded, misused, or mislabeled as such.

Bio Peptide Technologies is a chemical supplier. Bio Peptide Technologies is not a compounding pharmacy under Section 503A of the Federal Food, Drug, and Cosmetic Act, nor an outsourcing facility under Section 503B.

All products are sold for research, laboratory, or analytical purposes only.

YOU MUST BE OVER 21 YEARS OLD TO USE THIS WEBSITE.

1. Research Use Only: All products provided by Bio Peptide Technologies are intended solely for in-vitro laboratory research purposes. Any form of human or animal use, ingestion, or administration is expressly prohibited.
2. No Medical Claims: These materials are not intended to diagnose, cure, mitigate, treat, or prevent any disease or medical condition